Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Common Equity history runs 14 years deep, the most recent figure standing at $636.0 million for Q1 2026.

• On a quarterly basis, Common Equity rose 5.22% year-over-year to $636.0 million in Q1 2026; TTM through Mar 2026 was $636.0 million, a 5.22% increase from a year earlier, with the FY2025 full-year figure at $722.2 million, up 7.52% from the prior year.
• Common Equity declined to $636.0 million in Q1 2026 per VRDN's latest filing, from $722.2 million in the prior quarter.
• Across five years, Common Equity topped out at $722.2 million in Q4 2025 and bottomed at $141.9 million in Q2 2022.
• The 5-year median for Common Equity is $503.0 million (2025), against an average of $469.2 million.
• Across the five-year window, Common Equity sank 30.67% in 2023 and jumped 149.49% in 2024, its largest moves.
• Year by year, Common Equity stood at $395.1 million in 2022, then rose by 11.89% to $442.0 million in 2023, then jumped by 51.95% to $671.6 million in 2024, then advanced by 7.52% to $722.2 million in 2025, then declined by 11.93% to $636.0 million in 2026.
• Per Business Quant, the three latest VRDN Common Equity figures stand at $636.0 million (Q1 2026), $722.2 million (Q4 2025), and $503.0 million (Q3 2025).